These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 27687988

  • 1. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
    Rouvas A, Gouliopoulos NS, Moschos MM, Theodossiadis P.
    BMC Ophthalmol; 2018 Oct 12; 18(1):267. PubMed ID: 30309335
    [Abstract] [Full Text] [Related]

  • 4. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y, Sugiyama A, Tanabe N, Kikushima W, Kume A, Iijima H.
    Retina; 2017 Oct 12; 37(10):1866-1872. PubMed ID: 28002268
    [Abstract] [Full Text] [Related]

  • 5. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K, Kaneko H, Kataoka K, Ueno S, Chang-Hua P, Ito Y, Terasaki H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar 12; 255(3):449-455. PubMed ID: 27538907
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P, Anantharaman G, Gopalakrishnan M, Goyal A.
    Indian J Ophthalmol; 2018 Aug 12; 66(8):1119-1127. PubMed ID: 30038155
    [Abstract] [Full Text] [Related]

  • 7. One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study.
    Oshima Y, Kimoto K, Yoshida N, Fujisawa K, Sonoda S, Kubota T, Murata T, Sakamoto T, Yoshida S, Sonoda KH, Ishibashi T.
    Ophthalmologica; 2017 Aug 12; 238(3):163-171. PubMed ID: 28697497
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT study group.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar 12; 255(3):493-502. PubMed ID: 27628062
    [Abstract] [Full Text] [Related]

  • 9. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V, Upaphong P, Patikulsila D, Jirarattanasopa P, Choovuthayakorn J, Watanachai N, Kunavisarut P, Ratanasukon M, Bhurayanontachai P, Ingviya T, Bressler SB, Bressler NM.
    Ophthalmol Retina; 2022 Jan 12; 6(1):21-28. PubMed ID: 33781929
    [Abstract] [Full Text] [Related]

  • 10. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct 12; 255(10):1891-1897. PubMed ID: 28669041
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK, EVEREST II study group.
    JAMA Ophthalmol; 2017 Nov 01; 135(11):1206-1213. PubMed ID: 28983556
    [Abstract] [Full Text] [Related]

  • 12. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb 01; 255(2):311-316. PubMed ID: 27534663
    [Abstract] [Full Text] [Related]

  • 13. Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.
    Sakai T, Kato N, Kubota M, Tsuneoka H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug 01; 255(8):1565-1571. PubMed ID: 28601912
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Lee WK, Cheung CMG, Ngah NF, Patalauskaite R, Margaron P, Koh A, EVEREST II Study Group.
    JAMA Ophthalmol; 2020 Sep 01; 138(9):935-942. PubMed ID: 32672800
    [Abstract] [Full Text] [Related]

  • 15. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
    Yoneda A, Wakiyama H, Kurihara J, Kitaoka T.
    Eur J Ophthalmol; 2020 Nov 01; 30(6):1473-1479. PubMed ID: 31476891
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study.
    Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, Gemmy Cheung CM, Zhang Z, Leal S, Ishibashi T, PLANET Investigators.
    Am J Ophthalmol; 2019 Aug 01; 204():80-89. PubMed ID: 30849345
    [Abstract] [Full Text] [Related]

  • 17. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, Okada AA, Iida T, Sekiryu T.
    Jpn J Ophthalmol; 2018 Sep 01; 62(5):584-591. PubMed ID: 29974277
    [Abstract] [Full Text] [Related]

  • 18. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.
    Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H.
    Jpn J Ophthalmol; 2020 Mar 01; 64(2):203-209. PubMed ID: 32016666
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K, Li Y, Zhou L, Zhong X, Huang C, Xu F, Lu L, Ge J, Jin C.
    BMC Ophthalmol; 2018 Jun 20; 18(1):144. PubMed ID: 29925341
    [Abstract] [Full Text] [Related]

  • 20. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S, Matsumiya W, Miki A, Honda S, Nakamura M.
    Jpn J Ophthalmol; 2019 Sep 20; 63(5):389-395. PubMed ID: 31376050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.